The endocannabinoid system is spread throughout your brain and body, but primarily throughout your central nervous system. The interaction between cannabinoids and receptors is what produces effects like the regulation of mood, pain, appetite, inflammation, and memory. Plant-based cannabinoids, found in cannabis plants, also interact with the receptors (whimsically named CB1 and CB2) in the endocannabinoid system, and each affects your body in different ways. CBD and its infamous cousin THC are the 2 most well-known cannabinoids.
A study from 2016 worked with 214 people with epilepsy. The study participants added oral doses of 2 to 5mg of CBD per day to their existing anti-epilepsy medications. The study’s researchers monitored the participants for 12 weeks, recording any negative side effects and checking on the frequency of their seizures. Overall, participants had 36.5 percent fewer seizures per month. However, severe adverse effects were recorded in 12 percent of the participants.
Martin Lee, co-founder of Project CBD, told Leafly that hemp fiber and seed contain no usable amounts of cannabinoids. “Cannabidiol can’t be pressed or extracted from hempseed,” he writes. “CBD can be extracted from the flower, leaves, and, only to a very minor extent, from the stalk of the hemp plant. Hemp oil start-ups lack credibility when they say their CBD comes from hempseed and stalk.”
As the CBD Pure Hemp Oil label warns, you should not take the supplement if you are breastfeeding or pregnant, as there isn’t enough information on how it could affect the baby. Also, some studies suggest a long-term heavy use of cannabis can have negative neuropsychologic and behavioral effects, and even cause acute pancreatitis, although the exact mechanisms are still unknown.
The studies on CBD for headache pain are still in their infancy, but with promising results so far. A 2017 study published in the Cannabis and Cannabinoid Research Journal worked with 26 people who were experiencing rebound headaches. The pain management results were better for the cannabis-nabilone formula over either ibuprofen or nabilone alone. (As a nerdy side note, the article is a great read if you’re interested in the history of cannabis as a pain reliever.)
The passing of SB 218 through the Kentucky legislature created a new subsection of KRS 260.850m to 260.289, in which the Industrial Hemp Advisory Board outlines the purpose of an industrial hemp research program, establish license provisions, and create new requirements and license application procedures. This state’s approach is for the potential medical and industrial applications.